Immutep to present positive results in melanoma trial

Company News

by Rachael Jones

Biotech company Immutep (ASX:IMM) today announces more mature data relating to Part B of its ongoing phase I TACTImel clinical study of the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in patients with melanoma.

Consistent with previous data reported at 6 months of combination treatment, patients in Part B continue to report positive results in terms of tumour reductions after 9 months of treatment.

The data will be presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 in London today.

The ongoing TACTI-mel trial evaluates the combination of efti with anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in 24 patients with unresectable or metastatic melanoma.

Shares in Immutep (ASX:IMM) are trading 3.45 per cent higher at 3 cents. 
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.